• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

埃博拉病毒病幸存者产生多功能抗体反应。

Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses.

机构信息

Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts.

Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana.

出版信息

J Infect Dis. 2020 Jan 1;221(1):156-161. doi: 10.1093/infdis/jiz364.

DOI:10.1093/infdis/jiz364
PMID:31301137
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7184900/
Abstract

Monoclonal antibodies can mediate protection against Ebola virus (EBOV) infection through direct neutralization as well as through the recruitment of innate immune effector functions. However, the antibody functional response following survival of acute EBOV disease has not been well characterized. In this study, serum antibodies from Ebola virus disease (EVD) survivors from Sierra Leone were profiled to capture variation in overall subclass/isotype abundance, neutralizing activity, and innate immune effector functions. Antibodies from EVD survivors exhibited robust innate immune effector functions, mediated primarily by IgG1 and IgA1. In conclusion, development of functional antibodies follows survival of acute EVD.

摘要

单克隆抗体可以通过直接中和以及募集先天免疫效应功能来介导对埃博拉病毒（EBOV）感染的保护。然而，急性 EBOV 疾病存活后抗体的功能反应尚未得到很好的描述。在这项研究中，对来自塞拉利昂的埃博拉病毒病（EVD）幸存者的血清抗体进行了分析，以捕获总体亚类/同种型丰度、中和活性和先天免疫效应功能的变化。EVD 幸存者的抗体表现出强大的先天免疫效应功能，主要由 IgG1 和 IgA1 介导。总之，急性 EVD 存活后会产生功能性抗体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb79/7184900/abd4e3c2e71a/jiz364f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb79/7184900/6b9db53fd491/jiz364f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb79/7184900/abd4e3c2e71a/jiz364f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb79/7184900/6b9db53fd491/jiz364f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb79/7184900/abd4e3c2e71a/jiz364f0002.jpg

相似文献

1
Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses.埃博拉病毒病幸存者产生多功能抗体反应。
J Infect Dis. 2020 Jan 1;221(1):156-161. doi: 10.1093/infdis/jiz364.
2
Ebola Virus-Specific Neutralizing Antibody Persists at High Levels in Survivors 2 Years After Resolution of Disease in a Sierra Leonean Cohort.埃博拉病毒特异性中和抗体在塞拉利昂队列中疾病缓解 2 年后仍保持高水平。
J Infect Dis. 2024 Oct 16;230(4):e929-e937. doi: 10.1093/infdis/jiae155.
3
Serological analysis of Ebola virus survivors and close contacts in Sierra Leone: A cross-sectional study.塞拉利昂埃博拉病毒幸存者及其密切接触者的血清学分析：一项横断面研究。
PLoS Negl Trop Dis. 2019 Aug 1;13(8):e0007654. doi: 10.1371/journal.pntd.0007654. eCollection 2019 Aug.
4
Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection.埃博拉病毒中和抗体在感染 40 年后于扎伊尔扬布库疫情幸存者中可检测到。
J Infect Dis. 2018 Jan 4;217(2):223-231. doi: 10.1093/infdis/jix584.
5
Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors.抗体 Fc 介导的效应功能与埃博拉病毒幸存者长期后遗症之间的关联。
Front Immunol. 2021 May 20;12:682120. doi: 10.3389/fimmu.2021.682120. eCollection 2021.
6
Ebola-Specific CD8+ and CD4+ T-Cell Responses in Sierra Leonean Ebola Virus Survivors With or Without Post-Ebola Sequelae.塞拉利昂埃博拉幸存者有无埃博拉后遗症患者体内的埃博拉特异性 CD8+和 CD4+ T 细胞应答。
J Infect Dis. 2020 Oct 1;222(9):1488-1497. doi: 10.1093/infdis/jiaa268.
7
Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.美国四名埃博拉病毒感染者的早期人类 B 细胞对埃博拉病毒的反应。
J Virol. 2019 Apr 3;93(8). doi: 10.1128/JVI.01439-18. Print 2019 Apr 15.
8
Inflammatory and Humoral Immune Response during Ebola Virus Infection in Survivor and Fatal Cases Occurred in Sierra Leone during the 2014⁻2016 Outbreak in West Africa.在 2014-2016 年西非埃博拉疫情期间，塞拉利昂的幸存者和死亡病例中，埃博拉病毒感染期间的炎症和体液免疫反应。
Viruses. 2019 Apr 23;11(4):373. doi: 10.3390/v11040373.
9
Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus.埃博拉病毒病恢复期患者血浆中针对西非马科纳变异株埃博拉病毒的特异性中和反应。
Virus Res. 2016 Feb 2;213:224-229. doi: 10.1016/j.virusres.2015.12.019. Epub 2015 Dec 29.
10
Analysis of CD8 T cell response during the 2013-2016 Ebola epidemic in West Africa.分析 2013-2016 年西非埃博拉疫情期间的 CD8 T 细胞反应。
Proc Natl Acad Sci U S A. 2018 Aug 7;115(32):E7578-E7586. doi: 10.1073/pnas.1806200115. Epub 2018 Jul 23.

引用本文的文献

1
A systematic review of the immuno-inflammatory dysfunction secondary to viral hemorrhagic fevers; Ebola and Lassa fever.对继发于病毒性出血热（埃博拉病毒病和拉沙热）的免疫炎症功能障碍的系统评价
PLoS Negl Trop Dis. 2025 Jun 25;19(6):e0013230. doi: 10.1371/journal.pntd.0013230. eCollection 2025 Jun.
2
A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose.一项采用晚期加强剂量的同源和异源丝状病毒疫苗的1期随机试验。
NPJ Vaccines. 2024 Dec 23;9(1):255. doi: 10.1038/s41541-024-01042-4.
3
Fc-FcγR interactions during infections: From neutralizing antibodies to antibody-dependent enhancement.

本文引用的文献

1
Antibody-mediated protection against Ebola virus.抗体介导的埃博拉病毒防护。
Nat Immunol. 2018 Nov;19(11):1169-1178. doi: 10.1038/s41590-018-0233-9. Epub 2018 Oct 17.
2
Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors.在刚果埃博拉病毒感染幸存者中存在泛丝状病毒血清中和抗体。
J Infect Dis. 2018 Nov 5;218(12):1929-1936. doi: 10.1093/infdis/jiy453.
3
Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection.针对埃博拉病毒 GP 的单克隆抗体的系统分析定义了有助于保护的特征。
感染过程中的Fc-FcγR相互作用：从中和抗体到抗体依赖增强作用
Immunol Rev. 2024 Nov;328(1):221-242. doi: 10.1111/imr.13393. Epub 2024 Sep 13.
4
NIAID/SMB Workshop on Multiscale Modeling of Infectious and Immune-Mediated Diseases.NIAID/SMB 传染病与免疫介导疾病多尺度建模研讨会。
Bull Math Biol. 2024 Mar 21;86(5):44. doi: 10.1007/s11538-024-01276-2.
5
Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection.SARS-CoV-2、埃博拉病毒和尼帕病毒感染的免疫保护相关性。
Front Immunol. 2023 Apr 17;14:1156758. doi: 10.3389/fimmu.2023.1156758. eCollection 2023.
6
Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates.针对埃博拉病毒可溶性糖蛋白的抗体与非人类灵长类动物的长期疫苗介导保护有关。
Cell Rep. 2023 Apr 25;42(4):112402. doi: 10.1016/j.celrep.2023.112402. Epub 2023 Apr 15.
7
Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination.接种加德西（Gardasil®）和卉妍康（Cervarix®）疫苗后HPV特异性抗体Fc效应器功能的差异。
NPJ Vaccines. 2023 Mar 15;8(1):39. doi: 10.1038/s41541-023-00628-8.
8
Innate and Adaptive Immunity during SARS-CoV-2 Infection: Biomolecular Cellular Markers and Mechanisms.新型冠状病毒2019感染期间的固有免疫和适应性免疫：生物分子细胞标志物与机制
Vaccines (Basel). 2023 Feb 10;11(2):408. doi: 10.3390/vaccines11020408.
9
Afucosylation of HLA-specific IgG1 as a potential predictor of antibody pathogenicity in kidney transplantation.HLA特异性IgG1的去岩藻糖基化作为肾移植中抗体致病性的潜在预测指标。
Cell Rep Med. 2022 Nov 15;3(11):100818. doi: 10.1016/j.xcrm.2022.100818.
10
BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age.BNT162b2 诱导的针对 SARS-CoV-2 的中和抗体和非中和抗体功能随年龄增长而下降。
Cell Rep. 2022 Oct 25;41(4):111544. doi: 10.1016/j.celrep.2022.111544. Epub 2022 Oct 5.
Cell. 2018 Aug 9;174(4):938-952.e13. doi: 10.1016/j.cell.2018.07.033.
4
A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus.Fc 功能在治疗性单克隆抗体预防埃博拉病毒中的作用。
Cell Host Microbe. 2018 Aug 8;24(2):221-233.e5. doi: 10.1016/j.chom.2018.07.009.
5
Analysis of CD8 T cell response during the 2013-2016 Ebola epidemic in West Africa.分析 2013-2016 年西非埃博拉疫情期间的 CD8 T 细胞反应。
Proc Natl Acad Sci U S A. 2018 Aug 7;115(32):E7578-E7586. doi: 10.1073/pnas.1806200115. Epub 2018 Jul 23.
6
Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies.VSV-Ebola 疫苗接种后人体抗体库鉴定出新的靶标和中和 IgM 抗体。
Nat Med. 2016 Dec;22(12):1439-1447. doi: 10.1038/nm.4201. Epub 2016 Oct 31.
7
Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.从2014年埃博拉病毒疫情的一名幸存者体内分离出强效中和抗体。
Science. 2016 Mar 4;351(6277):1078-83. doi: 10.1126/science.aad5788. Epub 2016 Feb 18.
8
Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies.Fc受体介导的组织吞噬作用作为预防和治疗HIV疫苗策略的有效机制。
Mucosal Immunol. 2016 Nov;9(6):1584-1595. doi: 10.1038/mi.2016.12. Epub 2016 Feb 17.
9
Human Ebola virus infection results in substantial immune activation.人类感染埃博拉病毒会导致大量免疫激活。
Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4719-24. doi: 10.1073/pnas.1502619112. Epub 2015 Mar 9.
10
Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge.通过黏膜给药的抗HIV二聚体IgA2和全身性IgG1单克隆抗体实现深度防御：恒河猴免受黏膜SHIV攻击的完全保护。
Vaccine. 2015 Apr 21;33(17):2086-95. doi: 10.1016/j.vaccine.2015.02.020. Epub 2015 Mar 11.